SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs - Quaterly Results

02 Aug 2023 Evaluate
Revenue reduced marginally to stand at Rs. 212.37 millions during the quarter ended June 2023. The figure stood at Rs. 218.78 millions during the year-ago period.The Net Loss for the quarter ended June 2023 is Rs. -17.20 millions as compared to Net Profit of Rs. 3.27 millions of corresponding quarter ended June 2022Operating profit for the quarter ended June 2023 decreased to 29.85 millions as compared to 66.04 millions of corresponding quarter ended June 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 212.37 218.78 -2.93 212.37 218.78 -2.93 805.93 1643.49 -50.96
Other Income 4.28 6.84 -37.43 4.28 6.84 -37.43 34.52 27.20 26.91
PBIDT 29.85 66.04 -54.80 29.85 66.04 -54.80 190.52 1002.19 -80.99
Interest 13.33 28.01 -52.41 13.33 28.01 -52.41 115.70 199.21 -41.92
PBDT 16.52 38.02 -56.55 16.52 38.02 -56.55 3.08 756.30 -99.59
Depreciation 33.35 34.14 -2.31 33.35 34.14 -2.31 135.16 153.89 -12.17
PBT -16.83 3.88 -533.76 -16.83 3.88 -533.76 -132.08 602.41 -121.93
TAX 0.37 0.61 -39.34 0.37 0.61 -39.34 0.78 203.38 -99.62
Deferred Tax -1.98 0.61 -424.59 -1.98 0.61 -424.59 -1.29 203.38 -100.63
PAT -17.20 3.27 -625.99 -17.20 3.27 -625.99 -132.86 399.03 -133.30
Equity 330.90 286.90 15.34 330.90 286.90 15.34 306.90 286.90 6.97
PBIDTM(%) 14.06 30.19 -53.44 14.06 30.19 -53.44 23.64 60.98 -61.23

Lyka Labs Share Price

58.16 0.56 (0.97%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×